🔍

WINDLAS - Windlas Biotech

📊 NSE: WINDLAS 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/14/2025 15:17

📢 Recent Corporate Announcements

Windlas Biotech Approves ₹47 Cr Buyback at ₹1,000/Share; Record Date April 24, 2026

🟢 POSITIVE ⭐ 8/10

BOARD_MEETING 📅 17 Apr 2026, 02:32 PM

Windlas Biotech's Board has approved a buyback of up to 4,70,000 equity shares at a price of ₹1,000 per share, representing 2.23% of the total paid-up capital. The total buyback size is capped at ₹47 crore, which constitutes 9.80% of the company's aggregate paid-up capital and free reserves. The buyback will be executed through the tender offer route, and the record date for eligibility is fixed as April 24, 2026. Notably, the promoters and promoter group have decided not to participate in this buyback, which likely increases the acceptance ratio for public shareholders.

Buyback price of ₹1,000 per share is likely at a significant premium to the current market price.
Total buyback size of ₹47 crore represents 9.80% of the company's total net worth as of March 31, 2025.
Record date for determining eligible shareholders is set for April 24, 2026.
Promoters holding 61.90% of the company will not participate, enhancing the potential acceptance ratio for retail investors.
15% of the buyback (70,500 shares) is reserved for small shareholders as per SEBI regulations.

💡 Investors looking to benefit from the buyback premium should ensure they hold the shares in their demat account by the record date of April 24, 2026. The non-participation of promoters makes this an attractive opportunity for retail shareholders due to a potentially higher acceptance ratio.

Windlas Biotech Approves ₹47 Crore Buyback at ₹1,000 Per Share via Tender Offer

🟢 POSITIVE ⭐ 8/10

BOARD_MEETING 📅 17 Apr 2026, 02:09 PM

Windlas Biotech's board has approved a buyback of up to 4,70,000 equity shares, representing 2.23% of the total paid-up capital. The buyback is priced at ₹1,000 per share, involving a total outlay of ₹47 crore, which is approximately 9.8% of the company's free reserves. Significantly, the promoters and promoter group have opted not to participate in this offer, which is likely to result in a higher acceptance ratio for public shareholders. The record date to determine eligibility has been set for April 24, 2026.

Buyback of 4,70,000 shares at a price of ₹1,000 per share via the Tender Offer route.
Total buyback size is ₹47 crore, representing 9.8% of the aggregate paid-up capital and free reserves.
Promoters and Promoter Group (holding 61.90% stake) will not participate in the buyback.
Record date for eligibility is fixed as April 24, 2026.
15% of the buyback is reserved for small shareholders as per SEBI regulations.

💡 Eligible shareholders should consider tendering their shares to capitalize on the premium buyback price. The non-participation of promoters makes this particularly attractive for retail investors due to the potential for a high acceptance ratio.

Windlas Biotech Schedules Virtual Group Investor Meeting for April 20, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 15 Apr 2026, 06:00 PM

Windlas Biotech Limited has scheduled a virtual group meeting with institutional investors and analysts on April 20, 2026, at 3:00 PM. The meeting is a routine engagement under SEBI (LODR) Regulations to discuss the company's performance using publicly available information. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during this session. This interaction provides an opportunity for institutional players to gain clarity on the company's operational trajectory.

Meeting scheduled for Monday, April 20, 2026, at 3:00 PM IST.
The interaction will be held in a virtual group format with various investors.
Compliance disclosure made under Regulation 30(6) of SEBI (LODR) Regulations, 2015.
Company confirmed that only publicly available documents will be used for discussions.

💡 No immediate action is required as this is a routine investor relations event. Investors should monitor for any post-meeting presentations or transcripts that may provide updated management commentary on the CDMO business.

Windlas Biotech to Close Trading Window from April 1, 2026, for FY26 Financial Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Mar 2026, 06:09 PM

Windlas Biotech Limited has announced the closure of its trading window for all designated persons starting April 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's financial results for the year ending March 31, 2026. The window will remain closed until 48 hours after the financial results are officially declared and made public. This is a standard regulatory procedure for listed companies to prevent insider trading during the earnings preparation period.

Trading window closure effective from April 1, 2026
Closure pertains to the financial results for the fiscal year ending March 31, 2026
Window to reopen 48 hours after the financial results become generally available
Complies with SEBI (Prohibition of Insider Trading) Regulations, 2015

💡 No action is required as this is a routine regulatory filing. Investors should await the announcement of the board meeting date for the release of FY26 financial results.

Windlas Biotech Shareholders Approve Re-appointment of 3 Directors with 99.99% Majority

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 20 Mar 2026, 12:54 PM

Windlas Biotech Limited has announced the results of its postal ballot, where shareholders overwhelmingly approved the re-appointment of three key board members. Mr. Ashok Kumar Windlass was re-appointed as Whole-time Director, while Mr. Vivek Dhariwal and Mr. Gaurav Gulati were re-appointed as Independent Directors. Out of 15,320,885 total valid votes cast, 15,320,883 votes (99.99%) were in favor of the resolutions. This ensures leadership continuity for the company starting May 2026.

Re-appointment of Ashok Kumar Windlass as Whole-time Director approved with 15,320,883 votes in favor.
Independent Directors Vivek Dhariwal and Gaurav Gulati re-appointed effective May 6, 2026.
High shareholder participation with 72.69% of total outstanding shares polled.
Near-unanimous support from institutional and promoter groups, with only 2 votes cast against the resolutions.

💡 The near-unanimous approval indicates strong shareholder confidence in the current leadership and governance. Investors should view this as a positive sign of stability and continuity in the company's strategic direction.

Windlas Biotech Allots 28,990 Equity Shares Under ESOP Schemes

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Mar 2026, 12:55 PM

Windlas Biotech Limited has allotted 28,990 equity shares of face value Rs. 5 each on March 13, 2026, following the exercise of stock options by employees. The allotment includes 4,115 shares under the 2021 ESOP Plan and 24,875 shares under the 2023 ESOP Scheme. This is a routine corporate action intended to fulfill employee incentive obligations. While this increases the total share capital, the dilution is marginal and expected as part of the company's compensation structure.

Total allotment of 28,990 equity shares on March 13, 2026
4,115 shares issued under the Employee Stock Option Plan 2021
24,875 shares issued under the WBL Employee Stock Option Scheme 2023
All shares have a face value of Rs. 5 each

💡 No action is required as this is a routine administrative allotment with negligible impact on the company's valuation. Investors should focus on the company's upcoming quarterly performance and growth guidance.

Windlas Biotech Seeks Approval for Director Re-appointments and ₹1.56 Cr Annual Remuneration

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 16 Feb 2026, 05:54 PM

Windlas Biotech has initiated a postal ballot to seek shareholder approval for the re-appointment of Mr. Ashok Kumar Windlass as Whole-time Director for a five-year term starting May 3, 2026. The proposal includes a fixed annual remuneration of ₹1.56 crore and requires a special resolution as he is over 75 years of age. Additionally, the company is seeking a second five-year term for Independent Directors Mr. Vivek Dhariwal and Mr. Gaurav Gulati. Shareholders can participate in remote e-voting from February 18 to March 19, 2026.

Proposed re-appointment of Mr. Ashok Kumar Windlass as WTD for 5 years with ₹1.56 crore annual salary.
Special resolution required for Mr. Windlass to continue in office beyond the age of 75 years.
Re-appointment of two Independent Directors, Vivek Dhariwal and Gaurav Gulati, for second 5-year terms.
Remote e-voting period set for February 18, 2026, to March 19, 2026, with a cut-off date of February 13.
Aggregate remuneration of promoter executive directors may exceed SEBI Regulation 17(6)(e) limits but will remain within Section 197 ceilings.

💡 Investors should monitor the voting results to ensure leadership continuity and evaluate if the proposed remuneration aligns with the company's performance. No immediate portfolio changes are necessary based on this routine governance update.

Windlas Biotech Issues Postal Ballot Notice for Re-appointment of Three Directors

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 16 Feb 2026, 05:20 PM

Windlas Biotech Limited has issued a postal ballot notice to seek shareholder approval for the re-appointment of three key board members. The proposal includes the re-appointment of Mr. Ashok Kumar Windlass as Whole-time Director effective May 3, 2026. Furthermore, the company seeks to re-appoint Mr. Vivek Dhariwal and Mr. Gaurav Gulati as Independent Directors starting May 6, 2026. The remote e-voting period for these resolutions is scheduled to run from February 18, 2026, to March 19, 2026.

Re-appointment of Mr. Ashok Kumar Windlass as Whole-time Director effective May 3, 2026
Proposed re-appointment of Independent Directors Vivek Dhariwal and Gaurav Gulati effective May 6, 2026
Remote e-voting period scheduled from February 18, 2026, to March 19, 2026
Cut-off date for determining shareholder voting eligibility was February 13, 2026

💡 This is a routine management continuity exercise; investors should monitor the voting results to ensure stable leadership remains in place. No immediate portfolio changes are recommended based on this administrative filing.

Windlas Biotech to Meet Dron Capital and Other Investors on February 19, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Feb 2026, 12:32 PM

Windlas Biotech Limited has scheduled a virtual meeting with institutional investors on February 19, 2026, at 3:30 PM. The meeting will include representatives from Dron Capital, Axia Capital, and Prad Capital. The company stated that the discussions will be based on publicly available information and documents. This is a routine regulatory disclosure under SEBI (LODR) Regulations, 2015.

Virtual meeting scheduled for February 19, 2026, at 3:30 PM IST.
Participating institutions include Dron Capital, Axia Capital, and Prad Capital.
Discussions will be restricted to information already in the public domain.
The schedule is subject to change based on exigencies from either side.

💡 No immediate action is required as this is a routine investor interaction. Investors should monitor for any post-meeting transcripts or presentations that may offer deeper insights into the company's operational outlook.

Windlas Biotech Schedules Virtual Investor Meet with Dron Capital and Others on Feb 19

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Feb 2026, 12:30 PM

Windlas Biotech Limited has scheduled a virtual meeting with institutional investors on February 19, 2026, at 3:30 PM. The meeting will include representatives from Dron Capital, Axia Capital, and Prad Capital. The company has clarified that the discussions will be based strictly on publicly available documents and information. This is a routine engagement aimed at maintaining transparency with the institutional investment community.

Virtual meeting scheduled for February 19, 2026, starting at 3:30 PM IST.
Institutional participants include Dron Capital, Axia Capital, and Prad Capital.
Discussions will be limited to information already available in the public domain.
The meeting is conducted under Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 No immediate action is required as this is a routine investor interaction. Investors may look for any post-meeting transcripts or presentations if the company chooses to publish them.

Windlas Biotech Q3 Revenue Up 20% to INR 233 Cr; Plant 6 Completion Set for FY26

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 02:45 PM

Windlas Biotech reported a strong Q3 FY26 with revenue growing 20% YoY to INR 233 crores, marking its 12th consecutive quarter of record revenue. The CDMO vertical led the performance with 23% growth, while the Exports segment surged 36% due to increased penetration in semi-regulated markets. Management confirmed that Plant 6 is on track for mechanical completion by the end of FY26, which will bring the total revenue capacity to approximately INR 1,100 crores. For the first 9 months of FY26, the company achieved an EPS of INR 24.02, representing a 12% YoY increase.

Q3 FY26 revenue grew 20% YoY to INR 233 Cr, while 9M FY26 revenue rose 19% to INR 666 Cr.
9M FY26 EBITDA (excluding ESOP expenses) stood at INR 89 Cr with a margin of 13.3%.
Exports vertical grew 36% in Q3 FY26, significantly outperforming domestic volume growth trends.
Plant 6 mechanical completion expected by end of FY26 with an estimated capex of INR 50-60 Cr.
Total revenue capacity target set at INR 1,000 Cr for oral solids and INR 100 Cr for injectables.

💡 Investors should focus on the successful commissioning and utilization of Plant 6 and the injectable facility as primary growth catalysts. The company's consistent 12-quarter revenue growth streak and expansion in high-margin exports make it a strong candidate for long-term portfolios in the CDMO space.

Windlas Biotech Faces Suspension of Codeine Syrup Production; ₹55.21 Cr Revenue Impact

🔴 NEGATIVE ⭐ 7/10

REGULATORY 📅 10 Feb 2026, 05:19 PM

Windlas Biotech has received a Show Cause Notice from the Food Safety & Drug Administration (Uttarakhand), resulting in the temporary suspension of Codeine-containing cough syrup manufacturing. This specific product line contributed ₹55.21 crore to the company's total revenue in the current financial year as of February 9, 2026. While the suspension is limited to this product category, the company is preparing a detailed response to address the regulatory concerns and resume operations. Investors should monitor the duration of this suspension as it affects a material revenue stream.

Temporary suspension of Codeine-containing cough syrup manufacturing by Uttarakhand authorities.
Affected product line contributed ₹55.21 crore to revenue in the current FY up to Feb 9, 2026.
Suspension is limited to Codeine-based products; other manufacturing operations remain unaffected.
Company is in the process of filing a detailed response to the Show Cause Notice within stipulated timelines.

💡 Investors should monitor the duration of the suspension as the affected revenue is significant. Watch for the company's formal response and any further regulatory actions or clearances from the Food Safety & Drug Administration.

Windlas Biotech Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 06 Feb 2026, 04:05 PM

Windlas Biotech Limited has officially released the audio recording of its conference call held for the Q3 and nine-month period ended December 31, 2025. The call focused on the company's unaudited consolidated and standalone financial results. This disclosure is a standard regulatory requirement following the analyst meet conducted on February 6, 2026. Investors can access the recording via the company's website to understand management's perspective on recent performance.

Audio recording of the Q3 and 9M FY2025-26 earnings call is now available online.
The call discussed financial results for the quarter and nine months ended December 31, 2025.
A written transcript of the proceedings will be shared with stock exchanges shortly.
The recording can be accessed at the dedicated link: https://windlas.com/audio-transcript/

💡 Investors should review the audio recording or the upcoming transcript to gain insights into management's commentary on the CDMO business and future growth guidance.

Windlas Biotech Re-appoints Founder and Two Independent Directors for 5-Year Terms

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 05 Feb 2026, 06:52 PM

Windlas Biotech has approved the re-appointment of its founder, Mr. Ashok Kumar Windlass, as Whole-time Director for a five-year term starting May 2026. The board also re-appointed Chairman Mr. Vivek Dhariwal and Mr. Gaurav Gulati as Independent Directors for their second five-year terms. These moves ensure leadership continuity and maintain a board with deep expertise in pharmaceutical manufacturing and business strategy. The re-appointments are subject to shareholder approval and will extend the current leadership's tenure until 2031.

Mr. Ashok Kumar Windlass re-appointed as Whole-time Director for a 5-year term from May 3, 2026, to May 2, 2031.
Chairman Vivek Dhariwal re-appointed as Independent Director for a second 5-year term starting May 6, 2026.
Gaurav Gulati re-appointed as Independent Director for a second 5-year term starting May 6, 2026.
The leadership team brings combined experience from major firms like Pfizer, Baxter, and Oyo Hotels.

💡 Investors should view this as a sign of management stability and continuity, which is beneficial for long-term strategic execution. No immediate action is required as the existing leadership remains in place.

Windlas Biotech to Dissolve Non-Operating US Subsidiary Windlas Inc.

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 05 Feb 2026, 06:44 PM

Windlas Biotech Limited has announced the dissolution of its wholly owned subsidiary, Windlas Inc. USA, following board approval on February 5, 2026. The subsidiary was non-operating and contributed zero revenue to the company's consolidated turnover in FY 2024-25. Its net worth was marginally negative at USD -1,923.10, representing 0% of the parent company's net worth. This move is a routine administrative action to streamline the corporate structure by removing inactive entities.

Board approved the dissolution of Windlas Inc. USA, a non-operating wholly owned subsidiary.
The subsidiary reported USD NIL turnover and 0% revenue contribution for FY 2024-25.
Net worth of the subsidiary stood at USD -1,923.10 as of the end of the last financial year.
No consideration or sale proceeds will be received from the dissolution process.
Application for dissolution will be filed under the laws of Delaware, USA.

💡 Investors should view this as a routine corporate cleanup of a non-active entity. It has no material impact on the company's financial health or core operations.

View All WINDLAS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

In H1 FY26, the Generic Formulation CDMO vertical grew 18% YoY, Trade Generics & Institutional grew 25% YoY, and the Exports vertical grew 23% YoY. For Q2 FY26, these segments grew 18%, 24%, and 13% YoY respectively, contributing to a total revenue of INR 222 Cr.

Geographic Revenue Split

The company is expanding its footprint in semi-regulated geographies through its Exports vertical, which grew 23% in H1 FY26. Domestic operations comprise the majority of revenue through CDMO and Trade Generics (INR 172 Cr in FY25).

Profitability Margins

Gross margin expanded by 70 bps YoY in H1 FY26 and 68 bps YoY in Q2 FY26. Historical PAT margins were 8.0% in FY25, 9.2% in FY24, and 8.3% in FY23. The company achieved a 30% ROCE and 27% ROE for H1 FY26.

EBITDA Margin

EBITDA margin (excluding ESOPs) stood at 12.7% in FY25 (INR 97 Cr) and H1 FY26 EBITDA reached INR 55 Cr, representing a 25% YoY growth. The margin has improved from 10.3% in FY20 to a steady 12.7% in recent years.

Capital Expenditure

The company utilized INR 50 Cr from IPO proceeds to fund capex for the new injectables facility. Total net cash used in investing activities was INR 74 Cr in FY25 and INR 92 Cr in FY24.

Credit Rating & Borrowing

ICRA reaffirmed an [ICRA]A+ (Stable) rating for long-term fund-based facilities (INR 58.70 Cr) and [ICRA]A1 for short-term unallocated facilities. Interest coverage was healthy at 43.5 times in FY21, and the company remains net debt-free with INR 237 Cr liquidity.

⚙️ Operational Drivers

Raw Materials

Raw materials and packaging materials are the primary inputs, representing approximately 62.1% of revenue (COGS of INR 472 Cr on INR 760 Cr revenue in FY25). Specific chemical names are not disclosed.

Capacity Expansion

Current annual installed operating capacity is 706.4 crore units across four manufacturing facilities in Dehradun. Expansion is focused on the new injectables segment to support profitability and scale ramp-up.

Raw Material Costs

COGS was INR 472 Cr in FY25 (62.1% of revenue), up from INR 396 Cr in FY24. Procurement strategies involve long-term relationships to manage pricing and supply terms for raw materials and packaging.

Manufacturing Efficiency

The company achieved an asset turnover of 3.8x in FY25. Efficiency is driven by a focus on high-volume complex generics and chronic/sub-chronic dosage forms (59% of portfolio).

Logistics & Distribution

Trade Generics are sold directly to stockists and distributors without medical representative support to maintain a low-cost distribution model.

📈 Strategic Growth

Expected Growth Rate

18-20%

Growth Strategy

Growth will be achieved through the ramp-up of the new injectable facility, expanding the Trade Generics brand portfolio (which grew from 128 brands in FY20 to 400 in FY25), and increasing export penetration in semi-regulated markets. The company targets high-margin complex generics (67% of portfolio) and chronic therapies.

Products & Services

Pharmaceutical formulations (tablets, capsules, liquids), injectables, and trade generic medicines across chronic and sub-chronic therapeutic areas.

Brand Portfolio

The company owns 400 brands in its Trade Generics segment and has IP rights for formulation technology across 99% of products sold, including 4,340 brands in Complex Generics.

New Products/Services

Foraying into the injectables segment and expanding the Trade Generics portfolio, which has seen a 40% CAGR in revenue over the last three years.

Market Expansion

Targeting high-growth semi-regulated geographies in the Exports vertical, which grew 23% in H1 FY26.

Market Share & Ranking

Windlas is one of the leading formulations CDMO players in the organized domestic market, though it remains a moderate-sized player overall with FY25 revenue of INR 760 Cr.

Strategic Alliances

Maintains long-standing customer relationships with leading pharmaceutical companies for CDMO services; specific partner names for JVs are not disclosed.

🌍 External Factors

Industry Trends

Large pharma companies are shifting capex toward high-end products like biosimilars and regulated markets, creating an ecosystem where they outsource standard formulations to established CDMOs like Windlas.

Competitive Landscape

Competes with other domestic CDMOs and generic manufacturers; market dynamics are shifting toward specialized CDMOs as large players outsource non-core manufacturing.

Competitive Moat

Moat is built on 25 years of expertise, IP rights on 99% of products, and high entry barriers in complex generics (67% of portfolio). Sustainability is supported by long-term CDMO contracts and brand ownership in Trade Generics.

Macro Economic Sensitivity

Sensitive to the growth of the Indian Pharmaceutical Market (IPM), which grew 7.7% in Q2 FY26. Volume sensitivity is high as the industry saw a 0.2% volume decline in the same period.

Consumer Behavior

Increasing demand for affordable high-quality generic drugs is driving the 40% CAGR in the Trade Generics vertical.

Geopolitical Risks

Exposure to semi-regulated markets in the Exports vertical (23% growth) introduces risks related to trade barriers and local regulatory changes in those regions.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by the Companies Act 2013 (Section 143) and WHO-GMP standards for pharmaceutical manufacturing. Compliance with quality standards is central to the CDMO strategy.

Environmental Compliance

Operates three WHO-GMP compliant plants, ensuring adherence to international manufacturing standards.

Taxation Policy Impact

Effective tax rate is approximately 23.7% based on FY25 PBT of INR 80 Cr and Tax of INR 19 Cr. The company previously received an INR 8 Cr tax benefit from the WHC merger.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the successful ramp-up and capacity utilization of the new injectable facility, which carries higher depreciation costs (INR 28 Cr in FY25 vs INR 13 Cr in FY24).